MOODY ALDRICH PARTNERS LLC - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 343 filers reported holding BIO-TECHNE CORP in Q3 2018. The put-call ratio across all filers is 1.17 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
MOODY ALDRICH PARTNERS LLC ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$256,869
-48.5%
3,775
-43.9%
0.05%
-51.5%
Q1 2023$499,002
-10.6%
6,726
-0.2%
0.10%
-10.6%
Q4 2022$558,363
+15.1%
6,737
+294.2%
0.11%
+13.0%
Q3 2022$485,000
-18.1%
1,7090.0%0.10%
-13.8%
Q2 2022$592,000
-20.7%
1,709
-0.9%
0.12%
+10.5%
Q1 2022$747,000
+10.5%
1,724
+32.0%
0.10%
+11.7%
Q4 2021$676,000
+5.3%
1,306
-1.4%
0.09%
+16.0%
Q3 2021$642,000
+7.5%
1,324
-0.1%
0.08%
-3.6%
Q2 2021$597,000
+16.1%
1,325
-1.5%
0.08%
+13.5%
Q1 2021$514,000
+43.6%
1,345
+19.3%
0.07%
+27.6%
Q4 2020$358,000
+27.4%
1,127
-0.5%
0.06%
-1.7%
Q3 2020$281,000
-12.2%
1,133
-6.6%
0.06%
-13.2%
Q2 2020$320,000
+31.7%
1,213
-5.5%
0.07%
-6.8%
Q1 2020$243,000
-14.1%
1,283
-0.5%
0.07%
+25.9%
Q4 2019$283,000
-18.4%
1,289
-22.5%
0.06%
-34.8%
Q2 2019$347,000
-7.5%
1,663
-12.1%
0.09%
-15.2%
Q1 2019$375,000
+36.4%
1,891
-0.3%
0.10%
+16.7%
Q4 2018$275,000
-39.0%
1,897
-14.2%
0.09%
-30.8%
Q3 2018$451,000
+30.7%
2,212
-5.1%
0.13%
+5.7%
Q2 2018$345,000
+10.2%
2,332
+12.4%
0.12%
-38.8%
Q1 2018$313,0002,0740.20%
Other shareholders
BIO-TECHNE CORP shareholders Q3 2018
NameSharesValueWeighting ↓
Ownership Capital B.V. 840,131$363,810,0004.80%
Montanaro Asset Management Ltd 89,950$38,952,0004.80%
Sandhill Capital Partners LLC 109,939$47,608,0004.09%
Brown Capital Management 918,328$397,673,0003.96%
STONE RUN CAPITAL, LLC 22,325$9,668,0003.57%
DF DENT & CO INC 686,484$297,275,0003.42%
Westwind Capital 27,741$12,013,0003.23%
MAIRS & POWER INC 657,962$284,924,0002.87%
Summit Creek Advisors LLC 58,133$25,174,0002.85%
Pembroke Management, LTD 76,250$33,019,0002.76%
View complete list of BIO-TECHNE CORP shareholders